Solventum Target of Unusually High Options Trading (NYSE:SOLV)

Solventum Corporation (NYSE:SOLVGet Free Report) saw some unusual options trading on Tuesday. Stock investors bought 3,171 call options on the company. This is an increase of 1,153% compared to the average volume of 253 call options.

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently bought and sold shares of the stock. CrossGen Wealth LLC purchased a new stake in shares of Solventum in the 4th quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in Solventum during the 3rd quarter valued at $25,000. Clearstead Trust LLC raised its stake in Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares during the period. JNBA Financial Advisors lifted its holdings in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new stake in shares of Solventum in the second quarter worth $28,000.

Solventum Price Performance

Shares of SOLV traded up $6.10 during trading hours on Tuesday, hitting $86.57. 535,453 shares of the company were exchanged, compared to its average volume of 1,396,965. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The company has a market capitalization of $14.99 billion, a PE ratio of 10.56, a PEG ratio of 1.20 and a beta of 0.66. The firm has a fifty day simple moving average of $77.55 and a 200-day simple moving average of $74.16. Solventum has a one year low of $62.38 and a one year high of $88.20.

Solventum (NYSE:SOLVGet Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the firm earned $1.34 earnings per share. Solventum’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts predict that Solventum will post 6.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on SOLV shares. Piper Sandler dropped their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus lowered their price target on Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Wedbush began coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price objective for the company. Finally, KeyCorp raised their target price on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $86.00.

View Our Latest Analysis on SOLV

Solventum Company Profile

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

Further Reading

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.